TY - JOUR T1 - Axes of Prognosis: Identifying Subtypes of COVID-19 Outcomes JF - medRxiv DO - 10.1101/2021.03.16.21253371 SP - 2021.03.16.21253371 AU - Emma Whitfield AU - Claire Coffey AU - Huayu Zhang AU - Ting Shi AU - Xiaodong Wu AU - Qiang Li AU - Honghan Wu Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/24/2021.03.16.21253371.abstract N2 - COVID-19 is a disease with vast impact, yet much remains unclear about patient outcomes. Most approaches to risk prediction of COVID-19 focus on binary or tertiary severity outcomes, despite the heterogeneity of the disease. In this work, we identify heterogeneous subtypes of COVID-19 outcomes by considering ‘axes’ of prognosis. We propose two innovative clustering approaches − ‘Layered Axes’ and ‘Prognosis Space’ – to apply on patients’ outcome data. We then show how these clusters can help predict a patient’s deterioration pathway on their hospital admission, using random forest classification. We illustrate this methodology on a cohort from Wuhan in early 2020. We discover interesting subgroups of poor prognosis, particularly within respiratory patients, and predict respiratory subgroup membership with high accuracy. This work could assist clinicians in identifying appropriate treatments at patients’ hospital admission. Moreover, our method could be used to explore subtypes of ‘long COVID’ and other diseases with heterogeneous outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHW and HZ are supported by a Medical Research Council and Health Data Research UK Grant (MR/S004149/2), an Industrial Strategy Challenge Grant (MC_PC_18029), and a Wellcome Institutional Translation Partnership Award (PIII054). The study was also funded by Legal and General PLC (research grant to establish the independent Advanced Care Research Centre at University of Edinburgh). The funder had no role in conduct of the study, interpretation or the decision to submit for publication. The views expressed are those of the authors and not necessarily those of Legal and General PLC. XW is supported by National Natural Science Foundation of China (grant number:81700006). QL is supported by National Key R&D Program (2018YFC1313700), National Natural Science Foundation of China (grant number: 81870064) and the "Gaoyuan" project of Pudong Health and Family Planning Commission (PWYgy2018-06).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Research Ethics Committee of Shanghai Dongfang Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData pre-processing, machine learning details and all relevant scripts are available at https://github.com/knowlab/covid-subtypes. Details of the cohort are described at https://covid.datahelps.life/. The patient data used in the study will not be available due to inability to fully anonymize in line with ethical requirements. Applications for research access should be sent to TS. https://github.com/knowlab/covid-subtypes https://covid.datahelps.life/ ER -